£7.0M
The financing will support the commercial rollout of synthetic affinity reagents and team expansion.
MIP Discovery
MIP Discovery develops synthetic affinity reagents for cell and gene therapies.
£7.0MTotal raised
MIP Discovery develops synthetic affinity reagents designed to serve as antibody alternatives for cell and gene therapy manufacturing. The company focuses on improving downstream processing to make advanced medicines more accessible.
Categories
Team
SA
Stephane Argivier
CEO
ME
Mike Evans
Chair